Cohort study of bevacizumab in combination with XELOX for metastatic colorectal cancer

Cohort study of bevacizumab in combination with XELOX for metastatic colorectal cancer - Cohort study of bevacizumab in combination with XELOX for metastatic colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003416

Enrollment

Registered

2010-04-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.colorectal cancer cytologically and or histrogically 2.bidimensionally measurable disease no prior treatment for metastatic disease 3.XELOX+BV can be treatable 4.written informed consents

Exclusion criteria

Exclusion criteria: 1.Synchronous or metachronous multiple cancers 2. Contraindication of bevacizumab oxaliplatin and capecitabine 3.Investigators considers not suitable for the study

Design outcomes

Primary

Measure	Time frame
ORR; overall response rate drug administration situation (drug compliance situation, post-treatment, etc )	—

Secondary

Measure	Time frame
liver resection rate R0 liver resection rate TTF:time to treatment-failure PFS:progression-free survival OS :Overall survival adverse effects	—

Countries

Japan

Contacts

Public ContactMasahito Kotaka Rieko Yoneda

Sano Hospital Digestive Disease Center

tomomakotaka6410@yahoo.co.jp078-785-1000

Outcome results